Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Aldesleukin in Patients With Metastatic Renal Cell Carcinoma and Metastatic Melanoma

This study has been completed.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals ) Identifier:
First received: December 21, 2006
Last updated: February 9, 2013
Last verified: February 2013
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Estimated Study Completion Date: No date given
  Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: February 9, 2013